Synonym
MMV665917; MMV 665917; MMV-665917;
IUPAC/Chemical Name
4-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N-(4-chlorophenyl)piperazine-1-carboxamide
InChi Key
ZDXWENNHTOBFEW-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16ClN7O/c17-12-1-3-13(4-2-12)19-16(25)23-9-7-22(8-10-23)15-6-5-14-20-18-11-24(14)21-15/h1-6,11H,7-10H2,(H,19,25)
SMILES Code
O=C(N1CCN(C2=NN3C(C=C2)=NN=C3)CC1)NC4=CC=C(Cl)C([H])=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Cryptosporidiosis, an enteric protozoon, causes substantial morbidity and mortality associated with diarrhea in children <2 years old in low- to middle-income countries. There is no vaccine and treatments are inadequate.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
357.80
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Oboh E, Schubert TJ, Teixeira JE, Stebbins EE, Miller P, Philo E, Thakellapalli H, Campbell SD, Griggs DW, Huston CD, Meyers MJ. Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin. J Med Chem. 2021 Aug 3. doi: 10.1021/acs.jmedchem.1c01136. Epub ahead of print. PMID: 34342443.
2: Love MS, Choy RKM. Emerging treatment options for cryptosporidiosis. Curr Opin Infect Dis. 2021 Jul 15. doi: 10.1097/QCO.0000000000000761. Epub ahead of print. PMID: 34261904.
3: Choy RKM, Huston CD. Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration. PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008252. doi: 10.1371/journal.pntd.0008252. PMID: 32614819; PMCID: PMC7332027.
4: Lee S, Ginese M, Girouard D, Beamer G, Huston CD, Osbourn D, Griggs DW, Tzipori S. Piperazine-Derivative MMV665917: An Effective Drug in the Diarrheic Piglet Model of Cryptosporidium hominis. J Infect Dis. 2019 Jun 19;220(2):285-293. doi: 10.1093/infdis/jiz105. PMID: 30893435; PMCID: PMC7368243.
5: Chavez MA, White AC Jr. Novel treatment strategies and drugs in development for cryptosporidiosis. Expert Rev Anti Infect Ther. 2018 Aug;16(8):655-661. doi: 10.1080/14787210.2018.1500457. Epub 2018 Jul 17. PMID: 30003818.
6: Jumani RS, Bessoff K, Love MS, Miller P, Stebbins EE, Teixeira JE, Campbell MA, Meyers MJ, Zambriski JA, Nunez V, Woods AK, McNamara CW, Huston CD. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01505-17. doi: 10.1128/AAC.01505-17. PMID: 29339392; PMCID: PMC5913971.
7: Stebbins E, Jumani RS, Klopfer C, Barlow J, Miller P, Campbell MA, Meyers MJ, Griggs DW, Huston CD. Clinical and microbiologic efficacy of the piperazine- based drug lead MMV665917 in the dairy calf cryptosporidiosis model. PLoS Negl Trop Dis. 2018 Jan 8;12(1):e0006183. doi: 10.1371/journal.pntd.0006183. PMID: 29309415; PMCID: PMC5774826.
